Cara Therapeutics Q2 2023 net loss $31.5M; revenue $6.9M down from $23.0M

Tvardi Therapeutics, Inc.

2023-Q2 EPS reported -$1.08 revenue$13,098,000

Net loss of $31.5M ($0.58 per share) vs $4.2M ($0.08 per share) in Q2 2022.
Total revenue $6.9M, down 70% YoY; Q2 2022 included $15M milestone.
KORSUVA injection net sales $11.4M; collaborative revenue $5.4M; vial orders up 46% QoQ.
Cash and marketable securities $101.7M at June 30, 2023, down from $156.7M at Dec 31, 2022.
CMS proposed ESRD PPS rule includes additional funding for TDAPA products; final rule expected Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tvardi Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $6.9 million (total revenue), net income ($31.5 million) net loss, EPS ($0.58) per basic and diluted share.

Period: the second quarter ended June 30, 2023
Revenue: $6.9 million (total revenue)
Net income: ($31.5 million) net loss
EPS: ($0.58) per basic and diluted share
Result: reported results

Exact text from the filing

or $(0.58) per basic and diluted share, compared to net loss of $4.2 million, or $(0.08) per basic and diluted share, for the same period in 2022. Revenues: Total revenue was $6.9 million and $23.0 million for the three months ended June 30, 2023 and 2022, respectively. Revenue primarily consisted of: · $5.4 million and $8.0 million of collaborative revenue

View on SEC.gov

Browse all earnings releases →

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-088342

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.